Verrica Pharmaceuticals Inc (1NE0)

Currency in EUR
5.8400
0.0000(0.00%)
Delayed Data·
1NE0 Scorecard
Full Analysis
Holds more cash than debt on its balance sheet
1NE0 is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
5.84005.8400
52 wk Range
3.234026.3000
Key Statistics
Bid/Ask
0.598 / 0.6225
Prev. Close
5.84
Open
5.84
Day's Range
5.84-5.84
52 wk Range
3.234-26.3
Volume
-
Average Volume (3m)
506
1-Year Change
-80.47%
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
1NE0 Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Analysts Sentiment
Currently not supported.
Members' Sentiments
Bearish
Bullish
ProTips
High shareholder yield
Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Buy
Technical Indicators
Buy
Moving Averages
Strong Buy

Verrica Pharmaceuticals Inc Company Profile

Verrica Pharmaceuticals Inc., a dermatology therapeutics company, engages in the development and sale of medications for the treatment of skin diseases in the United States. The company’s product pipeline includes YCANTH (VP-102), which is in phase III clinical trial for the treatment of common warts; and has completed phase II clinical trial for treating external genital warts, as well as for molluscum contagiosum. It also develops VP-315, an oncolytic peptide-based injectable therapy that is in phase II clinical trial for the treatment of dermatology oncologic conditions, which include basal cell carcinoma; and VP-103, a cantharidin-based product candidate for treating plantar warts. The company has a collaboration and license agreement with Torii Pharmaceutical Co., Ltd. for the development and commercialization of its product candidates for the treatment of molluscum contagiosum and common warts in Japan, including VP-102; and a license agreement with Lytix Biopharma AS to develop and commercialize VP-315 for dermatological oncology indications, such as non-metastatic melanoma and non-metastatic merkel cell carcinoma. Verrica Pharmaceuticals Inc. was incorporated in 2013 and is headquartered in West Chester, Pennsylvania.

Employees
71
Market
Germany

Compare 1NE0 to Peers and Sector

Metrics to compare
1NE0
Peers
Sector
Relationship
P/E Ratio
−1.3x−3.5x−0.5x
PEG Ratio
−0.020.040.00
Price/Book
−3.5x2.7x2.6x
Price / LTM Sales
4.1x1.8x3.3x
Upside (Analyst Target)
-73.7%40.6%
Fair Value Upside
Unlock11.7%5.3%Unlock

Earnings

Latest Release
Aug 12, 2025
EPS / Forecast
0.02 / --
Revenue / Forecast
12.70M / --
EPS Revisions
Last 90 days

1NE0 Income Statement

People Also Watch

1.980
VOR
-1.98%
4.010
ATAI
-0.99%
2.020
IPA
+1.51%
0.78
KLTO
-2.52%
6.690
HYPD
-4.97%

FAQ

What Stock Exchange Does Verrica Pharmaceuticals Inc Trade On?

Verrica Pharmaceuticals Inc is listed and trades on the Frankfurt Stock Exchange stock exchange.

What Is the Stock Symbol for Verrica Pharmaceuticals Inc?

The stock symbol for Verrica Pharmaceuticals Inc is "1NE0."

What Is the Verrica Pharmaceuticals Inc Market Cap?

As of today, Verrica Pharmaceuticals Inc market cap is 48.78M.

What Is Verrica Pharmaceuticals Inc's Earnings Per Share (TTM)?

The Verrica Pharmaceuticals Inc EPS (TTM) is -6.41.

From a Technical Analysis Perspective, Is 1NE0 a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Sell.

How Many Times Has Verrica Pharmaceuticals Inc Stock Split?

Verrica Pharmaceuticals Inc has split 1 times.

How Many Employees Does Verrica Pharmaceuticals Inc Have?

Verrica Pharmaceuticals Inc has 71 employees.

What is the current trading status of Verrica Pharmaceuticals Inc (1NE0)?

As of 15 Aug 2025, Verrica Pharmaceuticals Inc (1NE0) is trading at a price of 5.84, with a previous close of 5.84. The stock has fluctuated within a day range of 5.84 to 5.84, while its 52-week range spans from 3.23 to 26.30.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.